Evidence map›Paper›PMID 40421224›Full record

ArticleFrontiers in pharmacology2025

Development and application of a UHPLC-MS/MS method for the simultaneous determination of firmonertinib and its main metabolite AST-5902 in rat plasma: a study on the

Peng-Fei Tang, Su-Su Bao, Wei-Fei Xie, Zhong-Xiang Xiao, Xue-Meng Wu, Hong-Lei Ge

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Peng-Fei Tang *Department of Clinical Pharmacy Room, Affiliated Yueqing Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Su-Su Bao *Department of Clinical Pharmacy Room, Affiliated Yueqing Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Wei-Fei XieDepartment of Hematology and Chemotherapy, Affiliated Yueqing Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Zhong-Xiang XiaoDepartment of Clinical Pharmacy Room, Affiliated Yueqing Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xue-Meng WuDepartment of General Department, Market Supervision Administration of Yueqing City, Wenzhou, Zhejiang, China.
Hong-Lei GeDepartment of Clinical Pharmacy Room, Affiliated Yueqing Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Due to the potential occurrence of drug interactions, the combined application of firmonertinib and paxlovid carries a relatively high risk. Nevertheless, as of now, there has been no comprehensive research on the interaction between firmonertinib and paxlovid. Our aim was to establish and validate an accurate, stable, rapid and simple UPLC-MS/MS method for the simultaneous determination of firmonertinib and its metabolite AST-5902 in rat plasma, which was applied to the study of the

Indexed as

drug interactionsfirmonertinibpaxlovidpharmacokineticsUHPLC-MS/MS

Identifiers

PMID40421224
PMCPMC12104055

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.